1 |
Nayak L, Abrey LE, Iwamoto FM. Intracranial dural metastases [J]. Cancer, 2009, 115(9): 1947-1953.
|
2 |
Le Rhun E, Weller M, Brandsma D, et al. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours [J]. Ann Oncol, 2017, 28(suppl_4): iv84-iv99.
|
3 |
Brown DA, Lu VM, Himes BT, et al. Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis [J]. Clin Exp Metastasis, 2020, 37(2): 341-352.
|
4 |
Cheng CL, Greenberg J, Hoover LA. Prostatic adenocarcinoma metastatic to chronic subdural hematoma membranes [J]. J Neurosurg, 1988, 68(4): 642-644.
|
5 |
Boire A, Zou Y, Shieh J, et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis [J]. Cell, 2017, 168(6): 1101-1113. e13.
|
6 |
Chi YD, Remsik J, Kiseliovas V, et al. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis [J]. Cancer, 2021, 369: 276-282.
|
7 |
Lyndon D, Lansley JA, Evanson J, et al. Dural masses: meningiomas and their mimics [J]. Insights Imaging, 2019, 10(1): 11-31.
|
8 |
Purandare NC, Puranik A, Shah S, et al. Differentiating dural metastases from meningioma:role of 68Ga DOTA-Noe PET/CT [J]. Nucl Med Commun, 2020, 41(4): 356-362.
|
9 |
Van Bussel MTJ, Pluim D, Milojkovic Kerklaan B, et al. Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases [J]. Neurology, 2020, 94(5): e521-e528.
|
10 |
Malani R, Fleisher M, Kumthekar P, et al. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer [J]. J Neurooncol, 2020, 148(3): 599-606.
|
11 |
Seoane J, De Mattos-Arruda L, Le Rhun E, et al. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases [J]. Ann Oncol, 2019, 30(2): 211-218.
|
12 |
Boire A, Brandsma D, Brastianos PK, et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications [J]. Neuro Oncol, 2019, 21(5): 571-584.
|
13 |
Sakaguchi M, Maebayashi T, Aizawa T, et al. Whole-brain radiation therapy for breast cancer patients with dural metastasis without concomitant brain metastasis and leptomeningeal metastasis [J]. Anticancer Res, 2018, 38(11): 6405-6411.
|
14 |
Kapke JT, Schneidewend RJ, Jawa ZA, et al. High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature [J]. Hematol Oncol Stem Cell Ther, 2019, 12(4): 189-193.
|
15 |
Bazan F, Dobi E, Royer B, et al. Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer [J]. BMC Cancer, 2019, 19(1): 1029-1034.
|
16 |
Mrugala MM, Kim B, Sharma A, et al. Phase Ⅱ study of systemic high-dose Methotrexate and intrathecal Liposomal Cytarabine for treatment of leptomeningeal carcinomatosis from breast cancer [J]. Clin Breast Cancer, 2019, 19(5): 311-316.
|
17 |
Kumthekar P, Tang SC, Brenner AJ, et al. ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases [J]. Clin Cancer Res, 2020, 26(12): 2789-2799.
|
18 |
Chen IC, Lin CH, Jan IS, et al. Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis [J]. J Formos Med Assoc, 2016, 115(4): 243-248.
|
19 |
Chen TW, Jan IS, Chang DY, et al. Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival [J]. J Neurooncol, 2020, 148(1): 165-172.
|
20 |
Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J]. Lancet Oncol, 2012, 14(1): 64-71.
|
21 |
Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2017, 18(6): 732-742.
|
22 |
Morikawa A, De Stanchina E, Pentsova E, et al. Phase Ⅰ study of intermittent high-dose Lapatinib alternating with Capecitabine for HER2-positive breast cancer patients with central nervous system metastases [J]. Clin Cancer Res, 2019, 25(13): 3784-3792.
|
23 |
Ricciardi GRR, Russo A, Franchina T, et al. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review [J]. BMC Cancer, 2018, 18(1): 97-104.
|
24 |
Exman P, Mallery RM, Lin NU, et al. Response to Olaparib in a patient with germline BRCA2 mutation and breast cancer leptomeningeal carcinomatosis [J]. NPJ Breast Cancer, 2019, 5(1): 1-5.
|
25 |
Ji G, Zhang C, Guan S, et al. Erlotinib for progressive brain and leptomeningeal metastases from HER2-positive breast cancer after treatment failure with Trastuzumab and Lapatinib: experience and review of literature [J]. Clin Breast Cancer, 2018, 18(5): e759-e765.
|
26 |
Bergen ES, Berghoff AS, Medjedovic M, et al. Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases [J]. Clin Cancer Res, 2019, 25(9): 2737-2744.
|
27 |
Tolaney SM, Sahebjam S, Le Rhun E, et al. A Phase Ⅱ Study of Abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer [J]. Clin Cancer Res, 2020, 26(20): 5310-5319.
|
28 |
Troussier I, Canova C, Klausner G. Complete response of leptomeningeal carcinomatosis secondary to breast cancer [J]. Breast, 2020, 54: 328-330.
|
29 |
Le Rhun E, Wallet J, Mailliez A, et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer [J]. Neuro Oncol, 2020, 22(4): 524-538.
|
30 |
Zagouri F, Zoumpourlis P, Le Rhun E, et al. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression [J]. Cancer Treat Rev, 2020, 88: 102046-102058.
|
31 |
Figura NB, Rizk VT, Mohammadi H, et al. Clinical outcomes of breast leptomeningeal disease treated with intrathecal Trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy [J]. Breast Cancer Res Treat, 2019, 175(3): 781-788.
|
32 |
Bonneau C, Paintaud G, Tredan O, et al. Phase Ⅰ feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis [J]. Eur J Cancer, 2018, 95: 75-84.
|
33 |
Hofer S, Aebi S. Letter comments on EJC published article: Phase Ⅰ feasibility study for intrathecal administration of trastuzumab in patients with HER2-positive breast carcinomatous meningitis [J]. Eur J Cancer, 2018, 103: 279-280.
|
34 |
Abouharb S, Ensor J, Loghin ME, et al. Leptomeningeal disease and breast cancer: the importance of tumor subtype [J]. Breast Cancer Res Treat, 2014, 146(3): 477-486.
|
35 |
Figura NB, Rizk VT, Armaghani AJ, et al. Breast leptomeningeal disease: a review of current practices and updates on management [J]. Breast Cancer Res Treat, 2019, 177(2): 277-294.
|
36 |
Pan Z, Yang G, He H, et al. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study [J]. Int J Cancer, 2016, 139(8): 1864-1872.
|
37 |
Pan Z, Yang G, He H, et al. Intrathecal Pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase Ⅰ/Ⅱ study [J]. Ther Adv Med Oncol, 2020, 12: 1-14.
|
38 |
Wolf A, Donahue B, Silverman JS, et al. Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases [J]. J Neurooncol, 2017, 134(1): 139-143.
|
39 |
Song ZW, Yang SY, Du FL, et al. Radiotherapy for adult medulloblastoma: evaluation of helical tomotherapy, volumetric intensity modulated arc therapy, and three-dimensional conformal radiotherapy and the results of helical tomotherapy therapy [J]. Biomed Res Int, 2018, 2018: 1-8.
|
40 |
El Shafie RA, Bohm K, Weber D, et al. Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis [J]. Cancer Manag Res, 2019, 11: 789-801.
|
41 |
Le Rhun E, Devos P, Weller J, et al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors [J]. Neuro Oncol, 2020, 23(7): 1-13.
|